Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 195.00 190.00 200.00 195.00 195.00 195.00 2,556 07:34:46
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 317

Amryt Pharma Share Discussion Threads

Showing 4551 to 4569 of 6075 messages
Chat Pages: Latest  183  182  181  180  179  178  177  176  175  174  173  172  Older
DateSubjectAuthorDiscuss
13/5/2019
22:58
Really? from what I see Bronxville sold his shares close to 20 pence. On the other hand you have said .18 and .16 was the bottom from your charts.
chica1
13/5/2019
18:27
ITS A WINNER PAPPY
purple11
13/5/2019
18:26
Bronxville Posts: 956 Opinion: No Opinion Price: 12.50 There could be a big seller bailing Today 12:25 Looks like the MM's are trying to rope in some suckers.. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> I can't think of a better buy signal! LOL. Bronxville is a great contrarian indicator! You can't beat him. When he says buy, sell and when he says sell, buy! A breakout today on good volume. News on the way, or just a realisation that AMYT is cheap? Probably the latter. I'll post a new chart tonight.
papillon
13/5/2019
13:01
purple11 13 May '19 - 10:19 - 4430 of 4430 (Filtered)
papillon
13/5/2019
10:19
good luck pups
purple11
13/5/2019
10:15
At least someone is keen on AMYT, bazworth. 120k buy this morning.
papillon
12/5/2019
17:24
No further Lojuxta distribution deals and no further Lojuxta type licensing deals! Very, very, disappointing, bazworth! Will we have to wait for when the AP101 phase III Top Line Data is issued, sometime in Q4 2019, for the next significant news? Looking like it, unfortunately!
papillon
12/5/2019
10:48
Don’t mention the BB’s! Don’t hold many AMYT at the moment as I became bored! Used to have an absolute shedload! More fun elsewhere currently! My only disappointment with AMYT is that there has been no further distribution deals.
bazworth
10/5/2019
23:51
sp just going sideways awaiting news. How long will we have to wait? How long is a piece of string? Don't get too excited about those tight Bollinger Bands, bazworth! :-) free stock charts from uk.advfn.com
papillon
06/5/2019
10:06
The same endless drivle. I did a quick check bronxville has been warning about Amryt since it was trading close to 20p and you have been deriding him all the way down to 12p. Oh and the poor little old pensioner routine is getting tedious as well.
chica1
05/5/2019
16:59
That arch conspiracy theorist, Bronxville, on the lse bb is trying to imply that Amryt's prediction of H2 2019 for the issue of the AP101 TOP-LINE DATA READ OUT has now drifted out to February 2022 because the clinicaltrials.gov web site says that is the expected date for the completion of the American AP101 trial and hence FDA approval (if the trial is deemed to be successful). I've news for you, Bronxville! Amryt have NEVER predicted that they are hoping for FDA approval in H2 2019. Have a look at the Amryt RNS's to see if you can find any such prediction. I can't! What Amryt are predicting for H2 2019 is the top-line data read out! BIG DIFFERENCE! I'm afraid you'll have to find some other stick with which to beat Amryt. PS Whether Amryt fulfil that H2 2019 prediction, or if it drifts into H1 2020, I have no idea. I treat my small shareholding in Amryt as a punt. A pure gamble on the success, or otherwise, of AP101. However if AP101 proves to be a failure for treating EB I'm hopeful that the existence of Lojuxta and AP103 will limit too much of a drop in the AMYT share price (which will hopefully be significantly higher by then on speculative investor interest). We will be in H2 2019 in less than a month and I'm hopeful that the AMYT share price will then start to rise in anticipation of the top-line data read out. I've got just under 15k of Amryt shares. I might increase that to 50k once we get into H2 2019 and the AMYT share price (hopefully) starts to rise. I'll still treat that 50k as a punt, a pure gamble, but with limited downside if AP101 turns out to be a dud.
papillon
04/5/2019
20:52
He thrives on confrontation.Probably undiagnosed Paranoid Personality Disorder. The other guy is doing work informing people and has been warning about Amryt for months.
chica1
03/5/2019
23:20
mdalos1 3 May '19 - 19:10 - 3 of 3 (Filtered) Bronxville Posts: 916 Opinion: No Opinion Price: 12.50 RE: Clinicaltrials.gov Today 18:53 Papillion the whole goal of the trial was getting FDA approval not EMA approval. They already have EMA approval for partial thickness wounds but they decided they needed FDA approval for EB to make Episalvan viable. My question is why so long Feb 2022 it is almost 3 years? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Whilst they have EMA approval for PTW's they DO NOT have EMA approval for EB, Bronxville. So the "goal of the (EASE) trial" is to gain both EMA & FDA approval, otherwise why would AMYT being conducting trials in Europe! I think you are being illogical, Bronxville, in saying it's solely to gain FDA approval. Why wouldn't AP101 be "viable" as a treatment for EB without FDA approval? After all AMYT can't sell Lojuxta in the America's (including the USA) and Japan because AMYT's license doesn't include those areas yet it's "viable" for AMYT to sell it in the rest of the world. Of course it's important to gain FDA approval because the USA is a big potential market for an effective EB treatment.
papillon
03/5/2019
18:28
Read this RNS, Bronxville. https://uk.advfn.com/stock-market/london/amryt-pharma-AMYT/share-news/Amryt-Pharma-PLC-Amryt-receives-IND-approval-from/78220498 Your February 2002 date only relates to the phase III AP101 trials being conducted in the USA. Trials were going ahead globally (as the RNS states) before the trials started in the USA. It just means that European approval will be received before approval in the USA if AP101 is deemed successful.
papillon
03/5/2019
11:50
Bronxville Posts: 912 Opinion: No Opinion Price: 12.50 Clinicaltrials.gov Today 09:22 Estimated AP101 study completion date February 2022 Curiousor and Curiousor >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> No it's not, curious, Bronxville as you well know! (learn to spell by the way!). This February 2022 completion date applies only to the phase III trials underway in the USA. hTTps://clinicaltrials.gov/ct2/show/NCT03068780?term=amryt&cond=Epidermolysis+bullosa&cntry=GB&rank=1 hTTps://clinicaltrials.gov/ct2/show/NCT03068780?term=amryt&cond=Epidermolysis+bullosa&cntry=GB&rank=1#contacts hTTps://clinicaltrials.gov/ct2/show/study/NCT03068780?term=amryt&cond=Epidermolysis+bullosa&cntry=GB&rank=1&show_locs=Y#locn PS. Have a look at this video, Bronxville. Top line data for AP101 expected H2 2019. Stop spreading lies, Bronxville! hTTps://www.ukinvestorshow.com/videos/amryt-pharma-plc/
papillon
03/5/2019
10:44
View Amryt Pharma's talk at The Global Group UK Investor Show: https://www.ukinvestorshow.com/videos/amryt-pharma-plc/
leeroy jenkins
02/5/2019
23:53
So tight Bollinger Bands get you excited, bazworth! :-). I wonder if there is such a thing as a porn site showing videos of tight Bollinger Bands? cbdrelief. FILTERED. He's made 603 posts since joining ADVFN on the 27/4/2019. That's 603 posts in less than a week. Apparently all on the same subject; the ramping of HNR on every ADVFN bb! Look at his posting history. Obviously ramping HNR is cbdrelief;s full time employment! LOL. It's unbelievable the frauds and conmen you get on these bb's. Why do ADVFN allow such blatant ramping to go unchecked?
papillon
02/5/2019
22:45
I adore tight Bollinger Bands! Let’s hope we spring free with huge upward momentum! Wake me up when we get started!
bazworth
02/5/2019
22:35
Tight Bollinger Bands, a rising RSI and the share price currently resting on support. free stock charts from uk.advfn.com
papillon
Chat Pages: Latest  183  182  181  180  179  178  177  176  175  174  173  172  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200925 08:10:37